Charles Schwab’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-589,007
| Closed | -$5.65M | – | 3542 |
|
|
2024
Q4 | $5.65M | Buy |
589,007
+21,944
| +4% | +$114K | ﹤0.01% | 2286 |
|
|
2024
Q3 | $1.62M | Buy |
567,063
+21,255
| +4% | +$65.8K | ﹤0.01% | 2767 |
|
|
2024
Q2 | $1.59M | Buy |
545,808
+13,215
| +2% | +$36.1K | ﹤0.01% | 2780 |
|
|
2024
Q1 | $1.7M | Buy |
532,593
+22,830
| +4% | +$76.1K | ﹤0.01% | 2642 |
|
|
2023
Q4 | $1.71M | Buy |
509,763
+6,687
| +1% | +$17.2K | ﹤0.01% | 2662 |
|
|
2023
Q3 | $1.2M | Buy |
503,076
+73,500
| +17% | +$154K | ﹤0.01% | 2745 |
|
|
2023
Q2 | $756K | Buy |
429,576
+168,830
| +65% | +$431K | ﹤0.01% | 2867 |
|
|
2023
Q1 | $803K | Sell |
260,746
-3,831
| -1% | -$23K | ﹤0.01% | 2814 |
|
|
2022
Q4 | $1.4M | Buy |
264,577
+5,286
| +2% | +$24.2K | ﹤0.01% | 2667 |
|
|
2022
Q3 | $916K | Buy |
259,291
+126,872
| +96% | +$420K | ﹤0.01% | 2816 |
|
|
2022
Q2 | $342K | Sell |
132,419
-87,671
| -40% | -$244K | ﹤0.01% | 3173 |
|
|
2022
Q1 | $987K | Buy |
220,090
+8,329
| +4% | +$37.6K | ﹤0.01% | 2852 |
|
|
2021
Q4 | $1.44M | Buy |
211,761
+2,826
| +1% | +$19.3K | ﹤0.01% | 2794 |
|
|
2021
Q3 | $1.52M | Buy |
208,935
+80,870
| +63% | +$694K | ﹤0.01% | 2758 |
|
|
2021
Q2 | $1.28M | Sell |
128,065
-13,451
| -10% | -$120K | ﹤0.01% | 2846 |
|
|
2021
Q1 | $1.35M | Buy |
141,516
+52,038
| +58% | +$510K | ﹤0.01% | 2758 |
|
|
2020
Q4 | $982K | Buy |
89,478
+1,500
| +2% | +$15.8K | ﹤0.01% | 2781 |
|
|
2020
Q3 | $781K | Buy |
+87,978
| New | +$1M | ﹤0.01% | 2733 |
|
Other funds holding PSTX
Charles Schwab's PSTX Position: Q1 2025 in Review
Charles Schwab sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 589,007 shares — an estimated $5.65M sold.
Charles Schwab first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $5.65M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Charles Schwab reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Charles Schwab sold 589,007 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $5.65M.
- Charles Schwab first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- Charles Schwab's Poseida Therapeutics, Inc. Common Stock position peaked at $5.65M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Charles Schwab's 13F filing for Q1 2025, filed 9 May 2025.